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Abstract
Background: Parkinson’s disease is the second most common long-term chronic, progressive, neurodegenerative
disease, affecting more than 10 million people worldwide. There has been a rising interest in wearable devices for
evaluation of movement disorder diseases such as Parkinson’s disease due to the limitations in current clinic
assessment methods such as Unified Parkinson’s Disease Rating Scale (UPDRS) and the Hoehn and Yahr (HY) scale.
However, there are only a few commercial wearable devices available, which, in addition, have had very limited
adoption and implementation. This inconsistency may be due to a lack of users’ perspectives in terms of device
design and implementation. This study aims to identify the perspectives of healthcare professionals and patients
linked to current assessment methods and to identify preferences, and requirements of wearable devices.
Methods: This was a qualitative study using semi-structured interviews followed by focus groups. Transcripts from
sessions were analysed using an inductive thematic approach.
Results: It was noted that the well-known assessment process such as Unified Parkinson’s Disease Rating Scale
(UPDRS) was not used routinely in clinics since it is time consuming, subjective, inaccurate, infrequent and dependent
on patients’ memories. Participants suggested that objective assessment methods are needed to increase the chance
of effective treatment. The participants’ perspectives were positive toward using wearable devices, particularly if they
were involved in early design stages. Patients emphasized that the devices should be comfortable, but they did not
have any concerns regarding device visibility or data privacy transmitted over the internet when it comes to their
health. In terms of wearing a monitor, the preferable part of the body for all participants was the wrist. Healthcare
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professionals stated a need for an economical solution that is easy to interpret. Some design aspects identified by
patients included clasps, material choice, and form factor.
Conclusion: The study concluded that current assessment methods are limited. Patients’ and healthcare
professionals’ involvement in wearable devices design process has a pivotal role in terms of ultimate user acceptance.
This includes the provision of additional functions to the wearable device, such as fall detection and medication
reminders, which could be attractive features for patients.
Keywords: Parkinson’s disease, Focus groups, Interviews, Healthcare professionals, Patients, Wearable devices,
Qualitative analysis, Preferences
Background
Parkinson’s Disease (PD) is the second most common
long-term chronic, progressive, neurodegenerative dis-
ease. It mainly affects the motor system, and the cardinal
motor symptoms are rest tremor, bradykinesia, rigidity,
and postural instability [1–3].
PD prevalence varies from 41 people per 100,000 in the
fourth decade of life to over 1900 people per 100,000 in
people over 80 years of age [1]. According to the Parkin-
son’s Foundation [4], more than 10 million people world-
wide are living with PD, and about one million people in
the United States (US) alone. The annual estimated direct
and indirect cost of PD in the US is $52 billion [4]. In
the United Kingdom, the estimated number in 2018 was
around 145,000; that is approximately one adult in every
350 [5].
PD is linked with morbidity, mortality, high economic
burden, and a decreased quality of life. However, studies
show that positive results can be achieved in the man-
agement of motor symptoms in the early stages. The
consequences of late or incorrect diagnosis have a neg-
ative impact on individuals’ patients and health service
system [6–8].
Clinical rating scales are essential to quantify neurolog-
ical disorders symptoms, impairment and disability [9].
Clinical rating scales in PD enable researchers and clini-
cians to evaluate disease symptoms, severity, progression,
treatment efficiency, response and side effects as well as
patients and their caregiver [9–11]. Several clinical rating
scales have been developed since the 1960s. The PD rating
scales can be categorised into impairment scales, disabil-
ity scales and multi-modular scales (impairment scales
and disability scales) [10]. The most commonly used rat-
ing scales of PD motor symptoms are: Hoehn and Yahr
(HY) [12] and Unified Parkinson’s Disease Rating Scale
(UPDRS) [13].
Hoehn and Yahr (HY) scale was designed originally
in 1967 to estimate the disease severity combining defi-
ciency and disability based on bilateral motor involvement
and compromised balance and gait [14]. It is a simple
scale describes the stage of PD from 1 to 5 based on
motor impairment severity and disability. The HY scale
has been used widely and has universal acceptance as a
scale to describe PD stages due to it is simplicity and abil-
ity to group PD patients based on motor and functionality
severity and progress [15]. The main advantage of the HY
scale is its ease of use, but it is a classification scale and
not a rank order [16], i.e., the stage does not reflect the
disability as someone in stage 2 may be more impaired for
activities of daily living (ADL) than someone in stage 3.
The Unified Parkinson’s Disease Rating Scale (UPDRS)
was published in 1987 and become the most widely
used rating scale [11]. However, the UPDRS scale has
some ambiguities and limitations. The Movement Disor-
der Society (MDS) has identified some of the limitations,
including ambiguities in questions, poor instructions and
the absence of important aspects of non-motor symp-
toms. Their findings have led to revised version MDS-
UPDRS to resolve identified problems in the UPDRS and
to enable better detection of small changes and mild
disabilities [13]. MDS-UPDRS consists of 65 elements
requires 30 min administration time distributed among
four parts; I) Non-motor experiences of daily living (13
elements), II) Motor experiences of daily living (13 ele-
ments), III) Motor examination (33 elements), IV) Motor
complications (6 elements) [13]. Each element scored
from 0 to 4 where (0: normal, 1: slight, 2: mild, 3: moder-
ate, and 4: severe), some elements are self-administrated
by patients without any help, and some elements are com-
pleted with or without help from a caregiver, but indepen-
dently from the examiner, and some elements are rated by
the examiner based on observation and physical examina-
tion. The MDS-UPDRS scale designed to avoid medical
terms to be easier for PD patients, and it applies to PD
patients with different levels of disabilities [9].
Even thoughMDS-UPDRS assessment is internationally
accepted rating scale to assess PD, and enhanced the qual-
ity of clinical trials outcomes, and has undergone strict
clinimetrics validation, but it is clinically based scale, that
the clinician assigns numerical scores based on qualita-
tive observations of the patient in various postures and
are often insensitive and subjective, so, the assessment
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depends on the examiners’ skills and knowledge, and it
is various from one examiner to another, so examiners’
disagreement on assessment and scores [17–19]. There
is evidence showed that MDS-UPDRS has high inter and
intra-rater variability between nurses’ and neurologists’
assessments [20–22]. Thus, a patient’s tremor may be
assigned MDS-UPDRS score by one examiner and in the
next appointment assessed by a different examiner and
assigned a higher score. In this situation, it is difficult to
interpret these two different scores, whether symptoms
worsen or due to subjectivity.
TheMDS-UPDRS scale is time-consuming and requires
lengthy administration time, approximately 30 minutes,
besides it requires specialised official training to improve
the coherence of data acquisition and interpretation, these
make it unhandy for routine clinical practice [13, 23].
Another time burden thatmany elements inMDS-UPDRS
need to be completed by patients, so additional time is
required besides the time required to review these ele-
ments by the examiner. This time burden limits the use of
the MDS-UPDRS in routine clinical practice. Therefore,
MDS-UPDRS scale is mainly used in clinical research. The
assessment performed in a clinical environment does not
mirror day to day symptoms, which might vary during the
day or the last few weeks or months and can only cap-
ture a snapshot of patient’s symptoms at thatmoment [15].
Moreover, many elements of the MDS-UPDRS scale do
not apply to each patient, so these questions may raise
anxiety in patients, consequently influence their assess-
ment, besides incompetent usage of examiner’s time.
Additionally, many elements in MDS-UPDRS scale
depends on patients memory, which is unreliable and lim-
ited by recall bias [17–19] due to that fact that most
patients are elderly, they exhibit cognition and demen-
tia issues. PD can also cause cognitive dysfunction even
in early stages which affect patients recall capabilities
[24, 25]. Also, long time between appointments makes
it difficult to remember symptoms during this period,
besides it is an inconvenience for patients to travel
to the clinic due to the weather conditions, trans-
portation, distance, and their conditions, particularly
in advanced stages of the disease [26]. Therefore, an
early objective and more detailed, accurate, and reli-
able diagnosis and assessment could be a contribut-
ing factor to help increase the chance of effective
treatment. This could decrease disability over time,
thus cutting down on direct and indirect healthcare
costs [3, 27].
Wearable technologies have been increasingly intro-
duced for more accurate motor assessment. They have
shown promising results in research and clinical trials to
objectively measure and monitor symptoms, both on-site
and remotely [18, 28–32]. However, a limited number of
commercial systems are available for such purposes [33]
such as SENSE-PARK system,1 Kinesia system,2 Parkin-
son’s Kinetigraph (PKG)3 and Physilog,4 and where they
do exist, they show limited adoption and implementa-
tion [34] despite of the fact that these devices shows high
reliability, validity and responsiveness [33, 35], and have
been used in the evaluation of PD symptoms and signs
by individuals apart from development team and reported
successful clinical trials [35, 36]. Data from several studies
suggest that these inconsistencies in adoption and imple-
mentation may be due to the lack of users’ perspectives in
devices design and development [37, 38].
Even though users’ preferences need to be considered if
wearable devices are to gain acceptance at home or within
a clinic [39, 40], a recent systematic review shows that the
research to date has tended to focus on wearable devices
development from quantitative perspectives such as type
of sensors, data extraction, and classification methods.
There is little attention paid to users’ preferences with
few studies reporting patients’ or clinicians’ experiences,
preferences, and expectations of using wearable devices
[31]. here is evidence that remote and continuous moni-
toring plays a crucial role in treatment quality of patients,
as well as reducing costs that afflict the healthcare sys-
tems by reducing hospitalizations and increasing patients’
satisfaction.In addition, remote and continuous monitor-
ing makes it possible for physicians to identify disease
and its progression early in life and to track changes over
time [41], for example, a study conducted by New England
Healthcare Institute (NEHI) demonstrated that remote
monitoring resulted in a 60% reduction in hospital re-
admissions in England with estimated annual saving of up
to £6.4 billion [42].
High-quality medical devices with high levels of
patients’ and healthcare professionals’ acceptance
requires engineering methods such as user-centered
design (UCD) philosophy [37, 43] that places an empha-
sis on patients’ and healthcare professionals’ individual
needs as well the environment where the devices will
be used. It is suggested that innovations that are often
driven by technology evolution may increase the ‘risks’
that researchers develop products that only a few people
need and are willing to use [44]. Product development
must also take into consideration users’ involvement in
the early stages of device design and development where
challenges and possibilities, ideas, and concepts are
presented and discussed, thus minimising costly device
modifications and reducing recalls. This could lead to
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A recent systematic literature review was conducted by
Johansson et al. [31] found that few studies have explored
patients’ preferences or healthcare professionals’ prefer-
ences or both [23, 39, 45–56]. However, such studies
remain narrow in focus dealing only with device accep-
tance rather than users’ needs, and in addition, most of
these studies have investigated either patients’ perspec-
tives or healthcare professionals’ perspectives and have
not included both in the same study. For example, some
studies [23, 46, 53] utilized questionnaires to get feedback
only from patients linked to existing developed wearable
devices and focusing on user satisfaction, comfort and
wearing the device publicly. Also, these studies did not
involve or explore the design requirements from patients’
point of view or from healthcare professionals. Con-
versely, some studies explored healthcare professionals’
perspectives, for example, Santiago et al. [52] conducted
a survey to evaluate the impact of using a commercially
available wearable device (KinetiGraph™ or PKG) in rou-
tine clinical appointments of PD patients from physicians’
point of view. The study has explored how a developed
device could add value to current assessment, but it did
not take into consideration the design aspects and what
are the requirements since it is limited by feedback about
gathered data.
Few studies explored the needs and the requirements
of patients and healthcare professionals. For example,
Bergmann et al. [39] used an online questionnaire to iden-
tify the preferences of medical wearable devices for people
affected with arthritis, so these preferences can be used
in devices design and developments. However, this study
did not take into consideration clinicians’ or physiother-
apists’ preferences, which ultimately might limit device
adoption. In addition, arthritis conditions such as joint
pain might influence arthritis patients’ preferences; for
example, the preferable part of the body to place the wear-
able device, which might be different from other diseases
such as PD. Similarly, Bruno et al. [45] used an online
survey to identify users’ perspectives toward digital tech-
nology and wearable devices, but in this study, people with
epilepsy, caregivers, and healthcare professionals were
included. However, most of these studies have utilised
questionnaires, and approaches of this kind carry with
them various well-known limitations [57]. For example,
questions understanding and interpretations, the diffi-
culty of conveying feelings and emotions, and they are not
flexible and do not allow probing to get in-depth informa-
tion [58]. In contrast, focus group discussions and inter-
views can explore a range of views, perceptions, thoughts,
and sentiments and can provide insight into complicated
subjects [59].
Few studies utilized focused group discussions to gain
an in-depth insight into patients’ perspectives, and these
can help to design and develop wearable devices with
high acceptance and adoption. For example, Papi et al.
[50] used focus group discussions to identify design
requirements and mode of use of wearable technology for
patients with osteoarthritis. Similarly, Thilo et al. [54] and
Xing et al. [55] have used the same approach to identify
elderly people perspectives toward wearable technologies,
but, of these only one study has explored PD patients’ and
healthcare professionals’ preferences in-depth, utilizing
focus group discussions [49].
Based on an extensive review of the literature and
the subsequent completion of the study, we are able
to present one of the first comprehensive qualitative
studies that has explored both patients’ and health-
care professionals’ perspectives. This is specifically linked
to current diagnosis and assessment methods, wear-
able devices design and materials, and the require-
ments and specification of a combined PD monitoring
solution.
Considering the aforementioned limitations, initially,
this study employed semi-structured interviews and focus
group discussions to identify the perspectives of health-
care professionals and patients linked to current diagno-
sis and assessment methods. It also helped to identify
their preferences, needs, and requirements of wearable
devices to ultimately assess and monitor symptoms of PD.




A holistic approach was adopted by first using exploratory
semi-structured interviews, and later focus group discus-
sions according to the procedure used by Lambert and
Loiselle [60]. The first step in this approach was to con-
duct four preliminary semi-structured individual inter-
views for healthcare professionals interviews topic guide,
see Additional File 1); three with healthcare professionals
(2 females, 1 male; age range: 52-61 years) were recruited
from the Royal Derby Hospital, and one interview with
65 years female Parkinson’s local supporter was recruited
from Parkinson’s UK, who closely works with PD patients
and is understanding of their needs and requirements in
different ways such as emotional support, informal dis-
cussions about patients worries and experiences. Also,
she arranges social events and invites healthcare profes-
sional speakers to provide information about PD. This
voluntary work enrich her experience and knowledge
about PD patients’ requirements. These interviews were
utilised to obtain further in-depth information on the
current diagnosis and assessment processes. The results
(themes) from the exploratory interviews were used to
generate a discussion guide for the patient focus groups
for patients focus groups topic guide, see Additional File
2). The interview with the local supporter was used to link
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healthcare professional with patients views and not to
generate themes.
The second step was to conduct three focus group dis-
cussions involving 12 PD patients (5 females, 7 males; age
range: 56-88 years) were recruited through Parkinson’s
UK, each lasting approximately 60 minutes. The discus-
sions followed a semi-structured topic guide to allow a
deeper insight into product design and development. The
topic guide was designed to elicit general discussion with
a more specific question as probes used if they were not
raised or discussed by participants as per the recom-
mendations of Braun and Clarke [59]. The demographic
information of participants is summarised in Table 1.
Data analysis
Audio recordings of the healthcare professionals’ inter-
views and patients’ focus groups were transcribed verba-
tim by the lead researcher, which enabled initial familiari-
sation with the data. The data was then analysed using
an inductive thematic approach following the six phases
guideline as outlined by Braun and Clarke [59]. This
involved familiarisation with the data by reading tran-
scripts multiple times and annotating initial ideas and
coding interesting elements in the data with a systematic
approach by:
1 Organising data in meaningful forms.
2 Grouping codes based on potential themes.
3 Organising data in meaningful forms.
4 Grouping codes based on potential themes.
5 Collecting data relevant to each theme.
6 Reviewing themes by refining themes or sub-themes
by splitting, combining themes and find the
relationship between themes.
7 Defining and writing up the themes.
8 Final analysis and connect analysis to the research
question.
The results from the interviews analysis were utilised
to design a focus group topic guide. Verbatim quotes are
indicated using the following notation: I indicates Inter-
view, G indicates focus group, F indicates female,M indi-
cates Male, and the number indicates the focus group or
interview number. For example, GF1 (Female from focus
group number one).
Results and discussions
This study investigated patients’ and healthcare profes-
sionals’ opinions toward the current diagnosis and assess-
ment process together with their preferences toward
wearable technology and their expectations and out-
looks on potential solutions. Limitations of existing solu-
tions and barriers to their use were explored alongside
wearable technology design requirements and expected
solution outcomes. Both groups of participants showed
an unanimously positive response towards the use of
wearable technology for remote continuous monitoring.
The results from interviews identified the following rel-
evant themes: (1) Current diagnosis and assessment are
dubious art, (2) The role of aesthetics and design for
acceptance and adoption (3) Patients and healthcare pro-
fessionals want wearable technology that eases and refines
treatments.
Current diagnosis and assessmentmethods are dubious art
A common view amongst interviewees was that the
current assessment is subjective, dependent on clinical
expertise, and thus, inconsistent. Also, there is much
scope for Type I (False Positive) and Type II (False Nega-
tive) errors in diagnosis.
“The consultation thing can be a little bit subjective.
We doubt each other’s assessment.” (IM1)
“Sometimes we see patients who have been diagnosed
with Parkinson’s disease, but later it turns out to be
not Parkinson’s.” (IF3)
”So, it is about listening to their story, making your
own assessment and discussing the options, which
might help. It is very much an art.” (IF4)
The interviews show the need for objective data for
diagnosis and to distinguish between tremor and other
abnormal movements such as essential tremor (ET). Prob-
ing questions about the reason behind this suggested
that it is very difficult to differentiate PD tremor from
ET tremor, especially in early disease stages, which is
consistent with other research that has reported a high
misdiagnosis rate of PD and ET to be approximately 25%
of cases [61].
Table 1 Participants demographic information
Data source Gender Male : Female Number of participants Age (year) Mean ± SD
(range)
PD Duration (year) Mean
± SD (range)
Focus Group 1 2 : 1 3
Focus Group 2 3 : 3 6 73.83 ±10.69 (56 - 88) 8.5 ±7.29 (2 - 24)
Focus Group 3 2 : 1 3
Interviews 1 : 3 4 57.75 ±6.29 (52-65) NA
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“[New assessment method] Will be able to tell the
difference between those types of movements. So, you
know, that would be, that will be helpful.” (IM1)
The current assessment and monitoring processes are
dependent on patients’ memories and diaries which are
not reliable, as previous studies suggested that 30-40% of
PD patients will develop dementia [24], besides the fact
that most patients are elderly and several lines of evidence
suggest that memory decline occurs in individuals older
than 60 years [62]. Also, many PD patients are unaware
of their symptoms often cannot distinguish between PD
signs and other abnormal activities [63].
“[Patients] Do not always remember precisely . . .
they [Neurologists] might see them six months or even
every 12 months . . . clinically we [Neurologists] asked
them to video the movement that they are talking
about.” (IM1)
This study supports evidence from previous observa-
tions that current diagnosis and assessment scales are
subjective, infrequent and depend on clinicians’ skills and
patients’ recall [17, 18, 64].
Sometimes consultants ask patients to video tremors
they are experience at home for assessment, but elderly
patients may often not be familiar with modern technol-
ogy such as wearable and social computing as exemplified
below, and also shown by [65].
“They do not always know, and a lot of these patients
are elderly, and they maybe get the instructions, or they
will not know how to video.” (IM1)
A highly surprising fact that emerged from the data
was that the health care professionals reported scale or
score systems were not commonly used for diagnosis and
assessment, including the UPDRS. Probing questions
about the reason behind this suggested that assessment
scales are time burden and need repetition. This result
may be explained by the fact that UPDRS is primarily
used for clinical trials and research.
“I do not give numbers [scores for the symptoms]
they [researchers] might do in a research study.” (IM1)
“We do not tend to use UPDRS routinely in the
clinic.” (IF4)
Late diagnosis was a common concern amongst
patients, due to late referral from general practitioners
(GPs), as most GPs were not suspecting Parkinson’s in the
first visits. However, most of the patients were diagnosed
correctly and quite quickly when they were examined by a
neurologist. Another reported problem was that patients
reported having symptoms years before they went to see
a doctor or were referred to a specialist.
“A pain in the shoulder, . . . the doctor gave me a
coat and an injection. That seemed to ease it, but then
I needed them. I did not do anything about it for a
moment. I just left it, and then I noticed that I was
walking, and my right arm was not moving . . . Then
the doctor told me I had a clot on my brain.” (GM1)
“Dr [Name] diagnosed me and provided me a pre-
scription for having some form of, what did he call it?
spinal plates. ” (GM3)
Concerns were expressed about infrequent assessment;
the patients reported that assessments were typically
carried out every six months. In addition, assessment
depends on a patient’s memory or diary and does not often
involve examination or physical assessment. Instead, it
mainly focuses on generic subjective patients reports (e.g.,
“how are you?” “have you got any issues?”). Consistently
with healthcare professionals’ reports, none of the partici-
pants mentioned UPDRS motor examination. A common
view amongst patient interviewees was that infrequent
assessment affects their treatment by not taking the right
medication and the right dose due to long-time between
appointments, and their symptoms might be controlled
during the first few months post-assessment but not
for the entire six months period. However, all patients
reported that they can call nurses between appointments
if they feel unwell or if they have any issues.
The patients, on the whole, demonstrated that they
experience “peaks and troughs” from hour to hour and
from day to day, and some of the symptoms appear at
a specific time of the day or when they are doing spe-
cific tasks; these patterns are not picked up during clinic
assessment.
“Because I have on and off [Symptoms fluctuation] I
have started going on and off, so I am m sort of up and
down, up and down. ” (GM1)
The role of aesthetics and design for acceptance and
adoption
From healthcare professionals’ point of view, wearable
devices would be acceptable to most patients, particularly
young patients. Device visibility may depend on the stage
of the disease; healthcare professionals believed patients
in more complex stages of PD would be more likely will-
ing to wear visible devices than would newly diagnosed
patients.
“So, it depends on what stage of Parkinson’s you are
talking about. So, if you are going to go to somebody
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newly diagnosed, they probably want something pretty
discreet. But somebody who is in the more mainte-
nance, more complex phase they may wear something
that is a bit more visible.” (IF3)
Device design is one of the most important factors
that determine whether patients are willing to wear the
device. In line with previous studies [23, 39, 48, 49, 54, 56]
healthcare professionals felt that the device must be com-
fortable, easy to use, non-invasive, and should easily
be worn under clothes without catching/snagging. The
device should also be water-resistant, washable, durable,
and easy to fasten to minimise daily disruption.
One main objective of this study was to determine the
most preferable and suitable part of the body to wear
the device without affecting data quality. All healthcare
professionals independently suggested the wrist would
be most appropriate, with some focusing on reasons of
patient comfort and others on detection of PD tremor
characteristics. Given that most typical tremor in PD is
called a ‘pill-rolling’ rest tremor involving movement of
the thumb and index finger, the wrist would be an appro-
priate location for the device as it could reliably pick
up this type of tremor. These viewpoints match those
reported in earlier studies [66, 67].
Healthcare professionals were familiar with what wear-
able devices are and their use and functionality, and they
showed awareness of some commercial devices used for
diagnosis and assessment, such as Parkinson’s Kineti-
graph (PKG). However, none had ever used these before
because they are expensive, and the reports are difficult
to interpret. All healthcare professionals reported that
wearable devices that available commercially have mostly
been used for advanced treatments such as deep brain
stimulation and advanced therapies.
“It is quite expensive. They do use it, [Neurologist’s
name] in [City name] he uses them a bit because he is
doing, um, he has access to very expensive treatment
and so he wants very objective data to give them the
expensive treatment . . . The software that they have
developed to interpret the device finding is quite com-
plicated” (IM1)
”But I think the biggest problem with that is that
you have to pay a certain amount of money for every
report. Neurologists at [Hospital name] use it when
they are thinking about advanced therapies” (IF4)
When asked about wearable technology, most patients
have not heard about or used wearable technology. Fol-
lowing an explanation of the purposes of this technology
as a part of this study, the majority of patients taking
part in this study stated that they would be willing to use
wearable technology and to be monitored 24/7, as long as
the device is not invasive or on an undesired part of body
(e.g., neck or ankle). Patients stated the preferred part of
the body was the wrist, as one would wear a watch; this
was echoed by every participant in this study. This fur-
ther supports healthcare professionals’ point of view. Also,
these results are in keeping with previous observational
studies [66, 67].
Issues related to technology such as violation of privacy,
difficulty in learning how to use technology, fear and
discomfort of using technology and lack of human inter-
action were not particularly prominent in the discussion.
Except for one patient who thought that the fear or dislike
of modern technologies (Techno-phobia) could be a
barrier for many elderly people, which echoes healthcare
professionals’ perspectives. What is interesting about this
result is the conflicting perspectives between healthcare
professionals and patients. In addition to the growth in
the number and proportion of older people [68] suggest
that technology acceptance and adoption maybe is not
related to techno-phobia, but due to different perspec-
tives and lack of training on new technologies, in addition
to technology designs that do not meet users’ needs and
requirements.
“Well, I do not think it is an issue. I mean if it is if
somebody is going to try it in the first place to see if it is
going to work for everybody . . . a lot of all the people
do not trust modern technology” (GM1)
Regarding wearable design aspects, there are a number
of similarities between interviews and focus group discus-
sions in terms of what patients would want, including for
the device to be comfortable, non-invasive, waterproof,
durable, small, and easy to fasten. Patients’ discussions
focused on the wearable hardware side more than did
healthcare professionals. For example, patients discussed
which materials are more comfortable, breathable, not
sweaty/sticky, soft and spongy, including cloth over metal,
leather, neoprene, reinforced material, stainless steel, rub-
ber and silicon. Even though they held differing views
about what material should be, common ground was to
use comfortable material. Moreover, all patients focused
on the device wearing style, which be easy to fasten as
the tremor affects their ability to fasten traditional clasps
such as a buckle or flip styles. Velcro and elasticated straps
were the most preferable styles to patients; for example,
it was pointed out that Velcro straps could be tight-
ened as needed. Some patients offered it would be better
if they were involved in the development stages of the
device. These findings are in line with previous studies
[23, 39, 48, 49, 54, 56] in which wearable tech-
nology’s acceptance was determined by appearance,
comfortability, size, and ease of fitting.
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“What about these plastic, leathery straps because
this all new stuff coming out. The only thing l would
like is a nice easy clasp because that I have got very
faster on it, because this is my worst hand so if I have
tried to do my watch, that is why I have gone facility
like this [He showed clasp of his watch] that I can wear
it easily, something sticks together” (GF3)
“I think it might be nice to have an insight into the
development stages of whatever the devices that you
are going to use so that we can have some input or
whether you take it onboard or not” (GM1)
None of the patients had any concerns about device
visibility. Perhaps somewhat remarkably, they wanted
the device to identify them as people affected by PD, so
it might indicate to the community they may need help.
Indeed, It has been shown that psychological support
would be helpful for people with PD, since emotions
affect the severity of the symptoms [69]. Also, it helps
those affected avoid unwanted and uncomfortable situ-
ations if people know about their disorder, for example,
the public might think they are drunk due to the nature of
their symptoms. The feeling of embarrassment in public
due to PD symptoms has also been described in other
studies of PD [70–72].
“If it is designed to do with Parkinson’s and in time
people got to know if they saw that on you, you got
Parkinson’s, he might need help” (GF3)
“That happened to me when I was going through the
park. People thought I am the people sitting on a bench
though I was drunk they call back to me, told me to
take more water with it, you know, just the usual gobby,
which in fact that upset me. I never went out actually
after that for a few days because it upset me that much”
(GF2)
Patients and healthcare professionals want wearable
technology that eases and refines treatments
When asked healthcare professionals about their expec-
tations and outlooks from potentials monitoring and
assessment solutions, remarkably all interviewees shed
new light on their expectations that the solution could
lead for a better or new treatment, and as discussed in
“The role of aesthetics and design for acceptance and
adoption” section that objective data is needed for expen-
sive treatment as reliable markers; therefore, the solution
could help improving current treatments or leading
for new ones. The expected solution could be used to
evaluate treatments efficacy in terms of medications and
rehabilitation.
“If the nurse altered the medication, and you can
detect if the medication reduced patient tremor a bit
or knew it did not, or the tremor is bit worse, and that
is what you kind of go on, and that is enough, you
know, because then you can either try medication try
relaxation techniques.” (IF3)
There were some suggestions from healthcare profes-
sionals that the solution should be easier to use, provide
“very concise” information, and be easy to interpret.
As mentioned in “The role of aesthetics and design for
acceptance and adoption” section, one of the main rea-
sons that interviewed healthcare professionals are not
using devices available commercially the complexity of
interpreting their data and results.
“It might be ideal to have something that measured
tremor in some way or whether somebody was having
an off and on, but it just needs to tell us that quickly
and simply, without needing a degree in mastery the
charts” (IF3)
”I think the information it would give would need to
be very concise. We would not have time to be going
through reams” (IF4)
Concerns regarding lack of information of symptom
fluctuations were widespread among healthcare profes-
sionals, supporting that symptoms fluctuate from time to
time during the day and from day to day. Results show
high interest from healthcare professionals in contin-
uous monitoring and its importance in diagnosis and
treatment decisions. This finding reflects evidence from
previous studies that showed the benefits of continuous
monitoring [41, 73].
“Lots of patients come to us with issues at certain
times of the day, whether it is tremor or slowness and
stiffness or fatigue or, or you know, being sleepy or you
know, all of which could be the symptom of Parkinson’s”
(IF4)
“A pattern to their off time and it might help the
nurse how to adjust the medication . . . If you had
something [a solution] that was a bit more technical
and a bit more useful in revealing symptoms.” (IF3)
Consistent with the literature [32, 41, 74], this research
found that remote monitoring has a pivotal role in PD
treatment as well as healthcare cost reduction, mainly
for large geographical areas, and it could help patients
who are not in the vicinity of a hospital to be diagnosed,
particularly in cases of severe symptoms that make travel
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difficult. Also, it is easier and more efficient use of time
for healthcare professionals to assess patients remotely
rather than traveling to their homes.
“Who is living way away, they might not be able
to come to the clinic too often. [Neurologist’s name]
in[City name] used it [Wearable device name] because
I think the geographical area that they cover is quite
large” (IF3)
Remote and continuous monitoring was a recurrent
topic throughout the discussions; patients seemed to
believe it would help clinicians identify their symptom
fluctuations and patterns during the day, and if the medi-
cation does not help patients to manage their symptoms,
continuous monitoring could enable clinicians to change
medication in a timely way. Also, it was suggested to track
symptom history over a period before a clinic visit, which
would ensure that clinicians do not miss any information
that might affect patients’ treatment.
“It would be better if it is 24/7 because then you go
to get the full picture of the 24 hours, aren’t you? . . .
Because it is very tiring if you have got Parkinson’s to
travel a long way in a day” (GF1)
“I think if that goes through on that and is something
the doctor picks up and appointment comes through to
see quite quickly because something in yourmedication
is not working as good as we think it could do.” (GF3)
There were some suggestions to other functionalities
to the device, such as fall detection and medication
reminders, as this information could help healthcare
professionals and patients alike, as forgetting medications
and falls are common in PD patients/older age generally
[54, 75].
“Something that counted falls would be useful
because patients do not remember how many falls they
have . . . Medication reminder would be useful and
does not stop until they have taken it” (IF3)
When asked patients about their expectations and
outlooks from potentials monitoring and assessment
solutions, a common view amongst patients was that
early precise diagnosis and accurate frequent assessment
could make their life easier and lead to better treatment,
as mentioned earlier by GF3 and below statement.
“Something that could make our life easier” (GM1)
“Privacy sort of goes out the window” (GM2) was
the response if the patients have any concern regarding
transferring the data over the internet or if someone
sees their data or PD information, unlike those in earlier
research [45, 49–51, 55]. The current patients seemed to
be comfortable forgoing their privacy rights in terms of
data access for the overall benefit of treatment. It was also
found that patients do not have concerns about device
visibility. On the contrary, patients made suggestions
the device should be visible to identify them as people
affected PD and that they may need help. This finding
contrasts with previous studies which emphasize patients’
preferences for the device to be discreet [39, 45, 50].
“I have Parkinson’s. I am not bothered who knows I
got Parkinson’s” (GM1)
“Privacy, no, I think you lose all your privacy when
you have got something like Parkinson’s” (GF2)
Supplementing the health care professionals’ interviews
results, it was suggested by patients to add a medication
reminder option to the wearable devices and the applica-
tions as patients report facing issues with remembering
taking the right medication on time. Additionally, patients
also suggested a help call button would be useful on the
device to summon an emergency contact when needed.
“I take my medication at set times during the day.
Well, this will be able to remind me which medication
to take on time” (GM2)
“I am wondering if you can put something on your
watch and, say, I fall in the house or outside. If a press
that button it goes straight through to my daughter’s
phone and I can speak to her” (GF3)
Previous research has established that user accep-
tance has a pivotal role in wearable technology adoption
[23, 39, 49, 52, 56]; however, very few studies focused
on wearable design methods, particularly the utilisation
of user-centered design (UCD) philosophy. The current
study offers some key insights into user involvement in
early design stages and to identify patients’ and health-
care professionals’ requirements and preferences, and the
importance of patients and medical professional input
was highlighted by participants in this study. Moreover,
the prior disregard of such input (alongside the down-
sides of costliness and difficulty of interpretation of com-
mercially available devices) may help explain the lack of
commonplace adoption of wearable technologies. If users
are involved in the design process, the device may bet-
ter suit their needs and overcome any barriers to their
use. Some options important to users may have previ-
ously been neglected by designers, such as medication
reminders and fall detection, which may further interest
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patients and healthcare professionals to use such wearable
devices.
In summary, these results show that current assessment
and monitoring processes are subjective and depend on
clinicians’ skills and experiences. It was commented that
“the consultation thing can be a little subjective”. Also,
they are not routinely applied in clinics because they
are time-consuming and rely on patients recall, as one
interviewee said: “We do not tend to use UPDRS rou-
tinely in the clinic”. The participants’ perceptions about
using wearable devices to evaluate symptoms were sup-
portive and suggested that this objective evaluation could
make the current assessment easier and enhance current
treatment. As one participant reported that “he wants
very objective data to give them the expensive treatment”.
Another important finding was that no concern was raised
about wearable devices visibility or private data conveyed
through the internet. For example, one interviewee said
“Privacy sort of goes out the window”. Participants were
interested in participating in device design, and they have
proposed many design aspects and options that increase
user acceptance and adoption. As one interviewee put
it “I think it might be nice to have an insight into the
development stages”.
Study limitations
We acknowledge that this exploratory study has sev-
eral limitations. First, The sample size may not be fully
representative of the wider PD and healthcare provider
population. Second, all participants were residing in the
Nottingham area. Hence, perceptions may differ in other
regions of the world which may limit the generalizability.
However, qualitative research rarely seeks to generalize
but to explore perceptions. Third,While interviewing par-
ticipants, we have noticed different levels of knowledge
and experience with technologies, so responses were likely
based on previous experience with available technolo-
gies, such as wearable devices or smartwatches. There-
fore, future research should attempt to include partic-
ipants from different regions, with different experience
and knowledge.
Conclusion
In conclusion, this qualitative study found that current
assessment and diagnosis methods are subjective and
depends on healthcare professionals’ skills, and this may
lead to inconsistent assessment. Currently, there is no
general agreement about a reliable, valid, sensitive and
cost-effective device to assess PD symptoms. Through this
study, healthcare professionals’ and patients’ perspectives
of wearable technology were positive and how it could
be utilised to improve the current assessment process,
thus increase the chance of effective treatment. A com-
mon view amongst interviewees was that participation in
the design process of wearable devices is a crucial aspect
of user acceptance. That involves fitting out additional
features for the wearable device, like fall detection and
medication alerts, which could be appealing to patients.
The outcomes from this research can help to design high-
quality wearable devices with a high level of patients’ and
healthcare professionals’ acceptance by considering users’
requirements and involving them in the design process.
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